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Schlumpf et al. (1,2) have reported the ultra-
violet sunscreen component 3-(4-methyl-
benzylidine)camphor (4MBC; structure
shown in Figure 1) to be uterotrophic when
administered either in diet to immature
Long-Evans rats or by whole-body immer-
sion of hairless hr/hr immature rats in an oil
solution. Subsequently, Bolt et al. (3) ques-
tioned the validity of those data and referred
to two negative unpublished immature rat
uterotrophic assays of 4MBC.
Our interest in 4MBC is to discern the
active uterotrophic species involved; 4MBC
is devoid of a hydroxyl group but possesses
the large camphor group, both of which
argue a priori against estrogenicity. When
the discussion between Bolt et al. (3) and
Schlumpf et al. (4) appeared, we had already
studied the binding properties of 4MBC to
isolated rat uterine estrogen receptors (ER),
its activity in a yeast ER-transactivation
assay, and its activity in both oral and subcu-
taneous immature rat uterotrophic assays.
Our data appear to be relevant to that dis-
cussion (3,4), which we describe here
together with a repeat of the MCF-7 breast
cancer cell proliferation assay of 4MBC
described by Schlumpf et al. (4).
Materials and Methods
Chemicals. We obtained 4MBC (CAS no.
38102-62-4; Merck batch no. TT805785
029) from ChemQuest (Wilmslow, Cheshire,
UK), and 17β-estradiol (E2), HEPES buffer,
arachis oil (AO), diethylstilbestrol (DES), and
(1R)-(+)-camphor (99%; structure shown in
Figure 1) from Sigma Chemical Company
(Poole, Dorset, UK). ChemService (West
Chester, PA, USA) supplied kepone (98%;
structure shown in Figure 1), and Amersham
Life Sciences (Bucks, UK) supplied
(2,4,5,7-3H)-estradiol (3H-E2; 88 Ci/mmol).
We obtained dimethyl sulfoxide (DMSO)
from Fisher Scientific (Loughborough,
Leicestershire, UK) and chlorophenol red-β-
galactopyranoside (sodium salt; CPRG)
from Roche Diagnostics (East Sussex, UK).
ER binding assay. We conducted the ER
competitive binding assay using the cytosol
isolated from the uteri of 21–25-day-old
female Alpk:APfSD rats (supplied by the
animal breeding unit at AstraZeneca
Pharmaceuticals, Macclesﬁeld, Cheshire, UK)
as described previously (5), using methods
based on those of Shelby et al. (6). We incu-
bated uterine cytosol with duplicate dose levels
of 4MBC (in 10 µL DMSO) and 3H-E2 (0.22
µCi; ≡ 5 × 10–9 M E2) at 4°C for 17 hr. We
then precipitated the receptor ligand with
hydroxylapatite, washed it well, and suspended
it in Optiphase (LKB Scintillation Products;
FSA Laboratory Supplies, Leics, UK) for the
determination of radioactivity in a Packard
Tri-carb 2100 TR liquid scintillation analyzer
(Packard Instruments, Pangbourne, UK). We
tested 10-fold dilutions of E2 and DES (5 ×
10–10 to 5 × 10–6 M) and 4MBC (5 × 10–10
to 5 × 10–4 M). We conducted two experi-
ments, each with duplicate dose levels of com-
pounds and of vehicle alone (DMSO) to
ascertain a 100% binding value. We deter-
mined the top dose level of 4MBC tested (5 ×
10–4 M) by the apparent limit of its solubility
in the assay medium.
Yeast ER transactivation assays. We
obtained the recombinant Saccharomyces
cerevisiae yeast strain harboring the human
ER from J. Sumpter (Brunel University,
Uxbridge, Middlesex, UK). The DNA
sequence encoding the human ER was inte-
grated into the genome of the Saccharomyces
cerevisiae yeast strain that also contained an
expression vector in which an ER response
element was cloned upstream of the reporter
gene LacZ (encoding the enzyme β-galac-
tosidase) (7). All glassware used in these
assays was dedicated purely for this purpose.
We prepared media components (8) and
performed the yeast assays as described pre-
viously by Routledge and Sumpter (7). We
serially diluted test chemicals and negative
controls in ethanol (except for the vehicle
control, HEPES, which we diluted in aque-
ous media). The top doses used in the assay
were 10–3 M for camphor, 4MBC, and
HEPES (control); 10–5 M for kepone; and
10–8 M for E2. 
We transferred 10 µL aliquots to 96-well
ﬂat-bottom microtiter plates (Linbro/Titertek,
ICN FLOW, Bucks, UK) and allowed to
evaporate to dryness. We then dispensed 200
µL aliquots of assay medium (i.e., medium
containing recombinant yeast and CPRG, the
chromogenic substrate) to each sample well.
We sealed the plates with autoclave tape and
shook them vigorously for 2 min prior to
incubation at 32°C for 3 days. At this point,
we measured color development of the
medium at an absorbance of 540 nm (using
a Labsystems iEMS Reader MF plate reader;
Labsystems Affinity Sensors, Cambridge,
UK). In addition, we measured absorbance
at 620 nm to assess turbidity (growth/viabil-
ity of the yeast). If the turbidity measure-
ment was decreased > 10% in any sample,
we discarded this result because of deleteri-
ous effects of the test chemical on yeast
growth and viability.
Cell proliferation assay. MCF-7 cells (a
gift from M. Parker, Imperial Cancer
Research Fund, London) in RPMI 1640
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In this study we found that the ultraviolet sunscreen component 3-(4-methylbenzylidine)camphor
(4MBC) is uterotrophic in immature rats when administered by either subcutaneous injection or
oral gavage. These data conﬁrm earlier reports of uterotrophic activity for this agent when admin-
istered to immature rats in the diet or by whole-body immersion; however, they are in contrast to
negative unpublished immature rat uterotrophic assay results. Data also indicate that 4MBC
binds to isolated rat uterine estrogen receptors and shows activity in a human estrogen receptor
yeast transactivation assay; however, we considered both of these effects equivocal. In this study,
we conﬁrmed the original observation that 4MBC was active as a mitogen to MCF-7 breast can-
cer cells. We evaluated and discounted the possibility that the estrogenic activity of 4MBC is
related to its bulky camphor group, which is of similar molecular dimensions to that of the weak
estrogen kepone. Uncertainty remains regarding the mechanism of the uterotrophic activity of
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with 10% (v/v) fetal calf serum, 100 U/mL
penicillin, and 100 µg/mL streptomycin. For
the cell proliferation experiments, we
trypsinized MCF-7 cells and suspended them
in RPMI media (phenol red-free) supple-
mented with 5% (v/v) charcoal-stripped fetal
calf serum, 100 U/mL penicillin, and 100
µg/mL streptomycin. We then seeded them
into 24-well plates at an initial concentration
of 30,000 cells/well. We cultured MCF-7
cells under these conditions for 5 days, then
incubated them with the appropriate concen-
tration of test compound for 6 days (media
changed every 3 days), as described by
Schlumpf et al. (4). We harvested cells by
trypsinization on day 6 and counted them
visually using a hemocytometer. We evalu-
ated statistical signiﬁcance relative to vehicle
(ethanol) control by a two-sided Student’s
t-test (p < 0.05 or p < 0.005).
Animals and dosing. We obtained 19- to
20-day-old (38–50 g) female Alpk:APfSD
(Wistar-derived) rats from the barriered ani-
mal breeding unit (AstraZeneca). The animals
were housed six per cage in solid-bottom
cages and allowed to acclimatize for 24 hr.
They were fed Rat and Mouse No. 1 (RM1
diet; Special Diet Services Ltd., Witham,
Essex, UK) and water ad libitum for the dura-
tion of the study. We homogenized 4MBC in
AO for at least 5 min using an Ultra Turrax
homogenizer (Janke and Kunkel, IKA-
Labortechnik, Germany). We stored dosing
solutions at room temperature and shook
them vigorously prior to dosing. We used a
dosing volume of 5 mL/kg body weight for
both routes of chemical administration.
We conducted preliminary dose setting
studies on 4MBC by exposing weanling rats to
4MBC for 3 days, as in the proposed
uterotrophic assays. We deﬁned the maximum
tolerated dose (MTD) for the oral gavage
studies as 1,000 mg/kg based on the absence
of an increase in body weight on the third day
of dosing. We therefore used dose levels equiv-
alent to 80% (800 mg/kg) and 50% (500
mg/kg) of the MTD for the oral gavage stud-
ies. We observed no toxicity for 4MBC up to
1,000 mg/kg by subcutaneous injection, so we
used dose levels of 500 mg/kg and 1,000
mg/kg for the subcutaneous injection study.
Each female received a single oral or subcuta-
neous injection of the appropriate compound
at the appropriate dose level on each of 3 days
(postnatal days 20–21 to 23–24). We used
DES as a positive control agent for the
uterotrophic assays (5 µg/kg dissolved in AO).
During the uterotrophic assays we modi-
ﬁed the test protocol so that animals exposed
to 800 mg/kg 4MBC by oral gavage received
moistened diet from day 3 of study. We
made this change in protocol because these
animals were failing to eat the pelleted diet
on the third day of dosing and thereby
showed signs of toxicity. Moistening the diet
led to a resumption of normal feeding.
Uterotrophic assays. All animals were ter-
minated by an overdose of fluothane
(AstraZeneca Pharmaceuticals) followed by
cervical dislocation (9) 24 hr after the last of
three daily administrations of the test agents.
We removed the uterus, trimmed it free of
fat, and gently blotted and weighed it. We
then placed the uterus in a preweighed vial,
dried it overnight (24 hr) at 70°C, and
reweighed it (9). We analyzed data by vari-
ance and covariance using the MIXED pro-
cedure of SAS (10). Speciﬁcally, we analyzed
uterine weights by covariance with the 
terminal body weights. We adjusted terminal
body weights for covariance with initial body
weights, and assessed differences from control
values statistically using a two-sided Student’s
t-test based on the error mean square from
the analysis of covariance. We considered the
individual to be the statistical unit.
Results
ER binding assays. The data from the ER
competitive binding assays are shown in
Figure 2. The data points are percentages of
the vehicle-alone value and represent the
means from the two separate experiments,
both of which gave both qualitatively and
quantitatively similar results. Both E2 and
DES treatments resulted in the binding char-
acteristics previously reported from this labo-
ratory (5). 4MBC reproducibly displaced E2
from ER, but no more than 20% displace-
ment could be achieved. We therefore could
not determine the concentration at which
50% inhibition occurs. Such instances have
been encountered before with phthalate esters
(11,12) where, as in this case, the compounds
were approaching their aqueous solubility
limits; in those cases the authors questioned
whether the apparent competitive binding of
the substrates to ER was artifactual. The pre-
sent data therefore provide only equivocal evi-
dence that 4MBC binds competitively to ER.
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Figure 1. Chemical structures of chemicals used in this study.
Figure 2. Estrogen competitive binding assay with 3H-E2, DES, and 4MBC using immature rat uterine
receptor preparations. The data are percentages of the vehicle (DMSO) control value and are the aver-
age of two separate experiments, each of which gave similar results.
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yeast assay data are shown in Figure 3. E2
gave the expected positive response, and the
HEPES vehicle controls behaved as expected
(5,7). Camphor was inactive, and kepone
showed weak activity in the assay. The toxic-
ity (reduced turbidity) of kepone precluded
evaluations of higher doses. 4MBC repro-
ducibly, but only marginally, increased opti-
cal absorbance, and we classiﬁed this response
as equivocal. We found no decreases in tur-
bidity in the 4MBC experiments, suggesting
that toxicity had not been a limiting factor.
The plateau nature of the assay response to
4MBC suggests that re-solution of the agent
into the medium may have become the limit-
ing factor in the assay response.
Cell proliferation assay. Proliferation of
MCF-7 cells was increased by incubation with
1–10 µM 4MBC for 6 days in culture (Figure
4). Cell numbers are expressed as mean ± SEM
for three counts per treatment group on day 6
of treatment. The results are representative of
several experiments. At concentrations above 2
× 10–5 M 4MBC, we observed a signiﬁcant
decrease in the number of viable cells (results
not shown), indicating that 4MBC may be
cytotoxic to these cells at high concentrations.
We observed maximal effects on MCF-7 cell
proliferation at 10 µM 4MBC in this system;
these levels of proliferation are similar to those
reported for 4MBC by Schlumpf et al. (4).
E2, at a concentration of 1 × 10–10 M, caused
MCF-7 cells to proliferate significantly,
compared to vehicle control (1 × 10–10 M E2;
1,037,600 ± 268,493 cells/well compared to
control 234,920 ± 36,249 cells/well; p < 0.05).
Uterotrophic assays. 4MBC was clearly
active in the immature rat uterotrophic assay
by both routes of exposure (Table 1, Figure
5). Both blotted and dry uterine weights were
increased in all test groups (p < 0.01). We
observed clinical signs of toxicity following
the third administration of 800 mg/kg
4MBC by oral gavage. One female from this
group was removed from the study shortly
after the third and final dose (data not
included in ﬁnal analyses; uterine weight was
63.9 mg). We then placed all females in this
group on moistened diet for the remainder of
the study. This change of protocol restored
normal eating patterns, suggesting that the
toxicity observed was caused by, or was exac-
erbated by, reduced food intake for this
group. At termination, we observed a statisti-
cally significant reduction in body weight
gain in both groups exposed to 4MBC by
oral gavage (Table 1). Given the signs of toxi-
city seen for the highest oral dose level of
4MBC in the main study (but not in the
dose-setting study), it would be preferable to
rely on the data generated at 500 mg/kg
4MBC (9% reduction in body weight and
no clinical signs of toxicity). We saw no indi-
cations of toxicity in females exposed to this
compound by subcutaneous injection, nor
did we see any adverse effects on body weight
(Table 1). DES gave the expected (5) increase
in uterine weight in the absence of evident
toxicity in each experiment (Table 1).
Discussion
The present results demonstrate that 4MBC
is uterotrophic to immature rats when admin-
istered by either oral gavage or subcutaneous
injection. These data therefore support posi-
tive uterotrophic results reported earlier for
4MBC when administered to immature rats,
either in diet or by whole-body immersion in
an oil solution (1). Within this context, the
two sets of unpublished and negative imma-
ture rat uterotrophic assay data for 4MBC
referred to by Bolt et al. (3) are of interest,
but they cannot be discussed further until
formally published. The relatively high dose
levels of 4MBC required to produce a partial
uterotrophic response suggest that it is a
comparatively weak rodent estrogen. The
mild toxicity seen for the highest oral dose of
4MBC is unlikely to have contributed to the
generation of the uterotrophic response,
because we saw similar uterotrophic activity
at the lower oral dose level. In addition, we
observed positive uterotrophic effects in the
subcutaneous injection studies, which were
in the absence of clinical signs of toxicity 
or changes in body weight. The present
uterotrophic assay data are insufficient to
Articles • Uterotrophic activity of 4MBC in the immature rat
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Figure 3. Human ER recombinant yeast assay for E2, 4MBC, kepone, and camphor (structures shown in
Figure 1). The control solution is HEPES buffer.
Figure 4. Effect of 4MBC on the proliferation of MCF-7 human breast cancer cells. Data are shown as the
mean ± SEM. 
*p < 0.05; **p < 0.005.
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Schlumpf et al. (1) were prompted to eval-
uate 4MBC in the uterotrophic assay based on
its clear activity in the MCF-7 cell prolifera-
tion assay in the dose range of 5 × 10–6 to 5 ×
10–5 M. The authors also demonstrated both
the induction of the estrogen responsive pS2
protein by 4MBC in MCF-7 cells and the
blockage of 4MBC-induced MCF-7 cell pro-
liferation by the antiestrogen ICI 182,780. In
the present ER binding and yeast ER transac-
tivation assays, we observed only equivocal evi-
dence for estrogenic activity for 4MBC, and
then only in the higher dose ranges of 5 × 10–5
to 5 × 10–4 M (ER binding) and 3 × 10–5 to
10–3 M (yeast assay). In the last two dose
ranges, insolubility may have precluded an
accurate assessment of the activity of 4MBC.
In contrast, we confirmed the clear activity
reported for 4MBC at 5 × 10–6 M in the
MCF-7 assay (4) in the present experiments.
This difference in assay outcomes between the
MCF-7 assay and the yeast assay of 4MBC
may be related to technical differences in the
respective assay protocols: in the MCF-7
assay, we added the test agents in medium to
the microwells, whereas the yeast assay proto-
col allows an ethanol solution of the test agent
to evaporate to dryness in the microwells, fol-
lowed by addition of the yeast cells in
medium (7,8,12). Alternatively, metabolic
transformation of 4MBC to an estrogenic
species may be occurring in the MCF-7 cells
but not in the yeast cells.
We also considered whether the estrogenic
activity of 4MBC may be associated with its
bulky terminal camphor group, this being
similar in shape to the weak uterotrophic
agent kepone (Figure 1) (6). On the basis of
“Dreiding” stereo-models, kepone and cam-
phor show similarities both in their molecular
non-space-filling dimensions and in their
three-dimensional shape (data not shown).
However, although kepone was active in the
yeast transactivation assay, camphor was inac-
tive. These observations weaken a possible
structural relationship of 4MBC to kepone.
In summary, 4MBC shows activity as a
weak uterotrophic agent to the immature rat
and mitogenic activity to MCF-7 cells treated
in vitro. However, we observed only equivocal
evidence of estrogenicity in vitro in ER bind-
ing and yeast transactivation assays. This
unusual combination of assay responses indi-
cates two main possibilities: ﬁrst, that 4MBC
is metabolized to an estrogenic intermediate in
MCF-7 cells and in rats but not in yeast cells
or in isolated uterine cytosol; second, that the
mechanism by which 4MBC elicits its activity
in MCF-7 cells and in rats is independent of
the ER. In connection with the latter possibil-
ity, it is interesting to note that in subchronic
studies of 4MBC, high doses were shown to
interfere with thyroid hormone regulation,
causing triiodothyronine (T3) levels to increase
despite maintenance of normal thyroxine (T4)
levels (13). Therefore, changes in these hor-
mones may be induced by 4MBC, which may
be responsible for its apparently selective estro-
genic activities. As suggested by Schlumpf et
al. (1,2,4), analysis of 4MBC in rodent repro-
ductive and developmental assays will be nec-
essary to advance assessment of its potential
endocrine toxicity to humans.
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Figure 5. 4MBC induces a signiﬁcant increase in blotted uterine weight when given to rats by either oral
gavage or subcutaneous injection; 500 mg/kg and 800 mg/kg are equivalent to 50% and 80% of the oral MTD.
We did not observe toxicity at doses up to 1,000 mg/kg when exposure was by subcutaneous injection. The
positive control agent, DES, gave the expected uterotrophic response. AO was used as the negative control.
**p < 0.01. 
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Table 1. Activity of 4MBC in the immature rat uterotrophic assay.
Dose  No. Uterine weight ±SD (mg)  Terminal body
Compound (kg) animals Blotted Dry weight ± SD (g)
Oral gavage route
AO 5 mL 12 22.0 ± 2.5 4.5 ± 0.4 55.9 ± 3.9
4MBC 500 mg 12 32.5 ± 6.5** 6.8 ± 1.0** 51.3 ± 4.8*
800 mg 11a 42.4 ± 6.0** 9.3 ± 3.0** 47.6 ± 4.4**
DES 5 µg 5 97.3 ± 7.7** 17.0 ± 1.4** 56.8 ± 4.1
Subcutaneous route
AO 5 mL 12 23.3 ± 4.3 4.9 ± 0.8 56.4 ± 3.2
4MBC 500 mg 12 31.1 ± 4.6** 6.0 ± 0.7** 56.9 ± 5.2
1,000 mg 12 29.4 ± 3.5** 5.6 ± 0.7** 56.5 ± 4.1
DES 5 µg 5 123.6 ± 8.2** 20.9 ± 1.7** 56.4 ± 5.3
aWe removed one female from this group 2 hr after the ﬁnal dose because of clinical signs of toxicity. The uterus was
removed at that time and weighed as 63.9 mg (blotted uterine weight). *p < 0.05; **p < 0.01.